Abstract Purpose of Review To summarize experimental and clinical evidence on the
association between tumor necrosis factor-α (TNF-α) and nonalcoholic fatty liver disease …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to
the global obesity epidemic. NAFLD comprises a systemic metabolic disease accompanied …

Abstract Purpose of Review Metabolic-associated fatty liver disease (MAFLD) is a condition
of fat accumulation in the liver that occurs in the majority of patients in combination with …

Obesity-related complications such as non-alcoholic fatty liver disease (NAFLD) and type 2
diabetes (T2D) are well-established risk factors for the development of hepatocellular …

The prevalence and severity of metabolic dysfunction associated steatotic liver disease
(MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the …

Background and aim The impact of chronic low-grade inflammation in the development of
non-alcoholic fatty liver disease (NAFLD) has been studied widely. Previous studies showed …

Background: Patients with cirrhosis and portal hypertension face a high risk of
complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce …

Ozonated sunflower oil (OSO) is an established therapeutic agent and nutraceutical
harboring various therapeutic values, including antiallergic, derma-protective, and broad …

Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are the most
common causes of chronic liver disease and are increasingly emerging as a global health …

Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent chronic liver
disease in Western countries, affecting approximately 25% of the adult population. This …